Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 953537, 17 pages
http://dx.doi.org/10.1155/2010/953537
Review Article

Nanotargeted Radionuclides for Cancer Nuclear Imaging and Internal Radiotherapy

1Center of Nanomedicine and National Institute of Cancer Research, National Health Research Institutes, 35053 Miaoli, Taiwan
2Isotope Application Division, Institute of Nuclear Energy Research, 32546 Taoyuan, Taiwan
3Biomedical Imaging and Radiological Sciences, National Yang-Ming University, 11221 Taipei, Taiwan

Received 13 April 2010; Accepted 15 June 2010

Academic Editor: David J. Yang

Copyright © 2010 Gann Ting et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Strebhardt and A. Ullrich, “Paul Ehrlich's magic bullet concept: 100 years of progress,” Nature Reviews Cancer, vol. 8, no. 6, pp. 473–480, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. G. P. Adams and L. M. Weiner, “Monoclonal antibody therapy of cancer,” Nature Biotechnology, vol. 23, no. 9, pp. 1147–1157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Reichert and V. E. Valge-Archer, “Development trends for monoclonal antibody cancer therapeutics,” Nature Reviews Drug Discovery, vol. 6, no. 5, pp. 349–356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Carter, “Potent antibody therapeutics by design,” Nature Reviews Immunology, vol. 6, no. 5, pp. 343–357, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. B. W. Newsome and M. S. Ernstoff, “The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?” British Journal of Clinical Pharmacology, vol. 66, no. 1, pp. 6–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Gabizon, H. Shmeeda, and Y. Barenholz, “Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies,” Clinical Pharmacokinetics, vol. 42, no. 5, pp. 419–436, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. T. M. Allen and P. R. Cullis, “Drug delivery systems: entering the mainstream,” Science, vol. 303, no. 5665, pp. 1818–1822, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. M. E. Davis, Z. Chen, and D. M. Shin, “Nanoparticle therapeutics: an emerging treatment modality for cancer,” Nature Reviews Drug Discovery, vol. 7, no. 9, pp. 771–782, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ferrari, “Cancer nanotechnology: opportunities and challenges,” Nature Reviews Cancer, vol. 5, no. 3, pp. 161–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Lammers, W. E. Hennink, and G. Storm, “Tumour-targeted nanomedicines: principles and practice,” British Journal of Cancer, vol. 99, no. 3, pp. 392–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Kairemo, P. Erba, K. Bergström, and E. K. J. Pauwels, “Nanoparticles in cancer,” Current Radiopharmaceuticals, vol. 1, no. 1, pp. 30–36, 2008. View at Google Scholar
  12. W. E. Bawarski, E. Chidlowsky, D. J. Bharali, and S. A. Mousa, “Emerging nanopharmaceuticals,” Nanomedicine, vol. 4, no. 4, pp. 273–282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. W. R. Sanhai, J. H. Sakamoto, R. Canady, and M. Ferrari, “Seven challenges for nanomedicine,” Nature Nanotechnology, vol. 3, no. 5, pp. 242–244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. E. Milenic, E. D. Brady, and M. W. Brechbiel, “Antibody-targeted radiation cancer therapy,” Nature Reviews Drug Discovery, vol. 3, no. 6, pp. 488–499, 2004. View at Google Scholar · View at Scopus
  15. J. Y. C. Wong, “Systemic targeted radionuclide therapy: potential new areas,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 2, supplement, pp. S74–S82, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. M. Macklis and B. Pohlman, “Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 3, pp. 833–841, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. J. Davies, “Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab,” Oncogene, vol. 26, no. 25, pp. 3614–3628, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl, “Comparison of Y90-ibritumomab tiuxetan and I131- tositumomab in clinical practice,” Journal of Nuclear Medicine, vol. 48, no. 11, pp. 1767–1776, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. H. Britz-Cunningham and S. J. Adelstein, “Molecular targeting with radionuclides: state of the science,” Journal of Nuclear Medicine, vol. 44, no. 12, pp. 1945–1961, 2003. View at Google Scholar · View at Scopus
  20. M. Hamoudeh, M. A. Kamleh, R. Diab, and H. Fessi, “Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer,” Advanced Drug Delivery Reviews, vol. 60, no. 12, pp. 1329–1346, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Mitra, A. Nan, B. R. Line, and H. Ghandehari, “Nanocarriers for nuclear imaging and radiotherapy of cancer,” Current Pharmaceutical Design, vol. 12, no. 36, pp. 4729–4749, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Liu, H. Miyoshi, and M. Nakamura, “Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles,” International Journal of Cancer, vol. 120, no. 12, pp. 2527–2537, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Sofou, “Surface-active liposomes for targeted cancer therapy,” Nanomedicine, vol. 2, no. 5, pp. 711–724, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Ogihara, S. Kojima, and M. Jay, “Differential uptake of gallium-67-labeled liposomes between tumors and inflammatory lesions in rats,” Journal of Nuclear Medicine, vol. 27, no. 8, pp. 1300–1307, 1986. View at Google Scholar · View at Scopus
  25. A. L. Klibanov, K. Maruyama, V. P. Torchilin, and L. Huang, “Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes,” FEBS Letters, vol. 268, no. 1, pp. 235–237, 1990. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Papahadjopoulos, T. M. Allen, A. Gabizon et al., “Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11460–11464, 1991. View at Google Scholar · View at Scopus
  27. D. Lasic, “Doxorubicin in sterically stabilized,” Nature, vol. 380, no. 6574, pp. 561–562, 1996. View at Google Scholar · View at Scopus
  28. W. T. Phillips, “Delivery of gamma-imaging agents by liposomes,” Advanced Drug Delivery Reviews, vol. 37, no. 1–3, pp. 13–32, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. O. C. Boerman, P. Laverman, W. J. G. Oyen, F. H. M. Corstens, and G. Storm, “Radiolabeled liposomes for scintigraphic imaging,” Progress in Lipid Research, vol. 39, no. 5, pp. 461–475, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Bao, B. Goins, R. Klipper, G. Negrete, M. Mahindaratne, and W. T. Phillips, “A novel liposome radiolabeling method using T99mc-“SNS/S” complexes: in vitro and in vivo evaluation,” Journal of Pharmaceutical Sciences, vol. 92, no. 9, pp. 1893–1904, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. W. T. Phillips, B. A. Goins, and A. Bao, “Radioactive liposomes,” Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, vol. 1, no. 1, pp. 69–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. B. R. Jarrett, B. Gustafsson, D. L. Kukis, and A. Y. Louie, “Synthesis of C64u-labeled magnetic nanoparticles for multimodal imaging,” Bioconjugate Chemistry, vol. 19, no. 7, pp. 1496–1504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. H.-Y. Lee, Z. Li, K. Chen et al., “PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles,” Journal of Nuclear Medicine, vol. 49, no. 8, pp. 1371–1379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. N. K. Devaraj, E. J. Keliher, G. M. Thurber, M. Nahrendorf, and R. Weissleder, “F18 labeled nanoparticles for in Vivo PET-CT imaging,” Bioconjugate Chemistry, vol. 20, no. 2, pp. 397–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. B. R. Line, A. Mitra, A. Nan, and H. Ghandehari, “Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates,” Journal of Nuclear Medicine, vol. 46, no. 9, pp. 1552–1560, 2005. View at Google Scholar · View at Scopus
  36. A. Almutairi, R. Rossin, M. Shokeen et al., “Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 3, pp. 685–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Cai, K. Chen, Z.-B. Li, S. S. Gambhir, and X. Chen, “Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature,” Journal of Nuclear Medicine, vol. 48, no. 11, pp. 1862–1870, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Chen, Z.-B. Li, H. Wang, W. Cai, and X. Chen, “Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 12, pp. 2235–2244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Ducongé, T. Pons, C. Pestourie et al., “Fluorine-18-labeled phospholipid quantum dot micelles for in vivo multimodal imaging from whole body to cellular scales,” Bioconjugate Chemistry, vol. 19, no. 9, pp. 1921–1926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. R. McDevitt, D. Chattopadhyay, B. J. Kappel et al., “Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes,” Journal of Nuclear Medicine, vol. 48, no. 7, pp. 1180–1189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Saad, O. B. Garbuzenko, E. Ber et al., “Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?” Journal of Controlled Release, vol. 130, no. 2, pp. 107–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Shokeen, N. M. Fettig, and R. Rossin, “Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 3, pp. 267–277, 2008. View at Google Scholar · View at Scopus
  43. M. A. Dobrovolskaia and S. E. McNeil, “Immunological properties of engineered nanomaterials,” Nature Nanotechnology, vol. 2, no. 8, pp. 469–478, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Lucignani, “Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 5, pp. 869–874, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. T. A. Elbayoumi, S. Pabba, A. Roby, and V. P. Torchilin, “Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents,” Journal of Liposome Research, vol. 17, no. 1, pp. 1–14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. T. A. Elbayoumi and V. P. Torchilin, “Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 10, pp. 1196–1205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Erdogan, A. Roby, and V. P. Torchilin, “Enhanced tumor visualization by γ-scintigraphy with I111n-labeled polychelating-polymer-containing immunoliposomes,” Molecular Pharmaceutics, vol. 3, no. 5, pp. 525–530, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Hu, M. Lijowski, H. Zhang et al., “Imaging of Vx-2 rabbit tumors with ανβ3- integrin-targeted I111n nanoparticles,” International Journal of Cancer, vol. 120, no. 9, pp. 1951–1957, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Li, C. A. Wartchow, S. N. Danthi et al., “A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated Y90-labeled nanoparticles,” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 4, pp. 1215–1227, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. X. Liu, Y. Wang, K. Nakamura et al., “Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with I111n,” Journal of Nuclear Medicine, vol. 50, no. 4, pp. 582–590, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. X. Pan, G. Wu, W. Yang, R. F. Barth, W. Tjarks, and R. J. Lee, “Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR,” Bioconjugate Chemistry, vol. 18, no. 1, pp. 101–108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Shukla, G. Wu, M. Chatterjee et al., “Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy,” Bioconjugate Chemistry, vol. 14, no. 1, pp. 158–167, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. K. J. Harrington, S. Mohammadtaghi, P. S. Uster et al., “Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes,” Clinical Cancer Research, vol. 7, no. 2, pp. 243–254, 2001. View at Google Scholar · View at Scopus
  54. J. Carlsson, E. F. Aronsson, S.-O. Hietala, T. Stigbrand, and J. Tennvall, “Tumour therapy with radionuclides: assessment of progress and problems,” Radiotherapy and Oncology, vol. 66, no. 2, pp. 107–117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Chen, R. Cameron, J. Wang, K. A. Vallis, and R. M. Reilly, “Antitumor effects and normal tissue toxicity of I111n-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts,” Journal of Nuclear Medicine, vol. 44, no. 9, pp. 1469–1478, 2003. View at Google Scholar · View at Scopus
  56. R. M. Reilly, P. Chen, J. Wang, D. Scollard, R. Cameron, and K. A. Vallis, “Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of I111n-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer,” Journal of Nuclear Medicine, vol. 47, no. 6, pp. 1023–1031, 2006. View at Google Scholar · View at Scopus
  57. R. M. Reilly, R. Kiarash, R. G. Cameron et al., “I111n-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR,” Journal of Nuclear Medicine, vol. 41, no. 3, pp. 429–438, 2000. View at Google Scholar · View at Scopus
  58. S. N. Reske, S. Deisenhofer, G. Glutting et al., “I111-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, β-, or γ-radiation-resistant cell lines,” Journal of Nuclear Medicine, vol. 48, no. 6, pp. 1000–1007, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. A. M. Smith, H. Duan, A. M. Mohs, and S. Nie, “Bioconjugated quantum dots for in vivo molecular and cellular imaging,” Advanced Drug Delivery Reviews, vol. 60, no. 11, pp. 1226–1240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. K. J. Harrington, C. R. Lewanski, and J. S. W. Stewart, “Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development,” Clinical Oncology, vol. 12, no. 1, pp. 2–15, 2000. View at Google Scholar · View at Scopus
  61. I. Ogihara-Umeda, T. Sasaki, S. Kojima, and H. Nishigori, “Optimal radiolabeled liposomes for tumor imaging,” Journal of Nuclear Medicine, vol. 37, no. 2, pp. 326–332, 1996. View at Google Scholar · View at Scopus
  62. K. J. Harrington, C. R. Lewanski, and J. S. W. Stewart, “Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development,” Clinical Oncology, vol. 12, no. 1, pp. 16–24, 2000. View at Google Scholar · View at Scopus
  63. M. M. Kleiter, D. Yu, L. A. Mohammadian et al., “A tracer dose of technetium-99m- labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation,” Clinical Cancer Research, vol. 12, no. 22, pp. 6800–6807, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. G. M. Jensen and T. H. Bunch, “Conventional liposome performance and evaluation: lessons from the development of Vescan,” Journal of Liposome Research, vol. 17, no. 3-4, pp. 121–137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. B. A. Goins, “Radiolabeled lipid nanoparticles for diagnostic imaging,” Expert Opinion on Medical Diagnostics, vol. 2, no. 7, pp. 853–873, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Urakami, S. Akai, Y. Katayama, N. Harada, H. Tsukada, and N. Oku, “Novel amphiphilic probes for [F18]-radiolabeling preformed liposomes and determination of liposomal trafficking by positron emission tomography,” Journal of Medicinal Chemistry, vol. 50, no. 26, pp. 6454–6457, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Oku, “Delivery of contrast agents for positron emission tomography imaging by liposomes,” Advanced Drug Delivery Reviews, vol. 37, no. 1–3, pp. 53–61, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Marik, M. S. Tartis, H. Zhang et al., “Long-circulating liposomes radiolabeled with [F18]fluorodipalmitin ([F18]FDP),” Nuclear Medicine and Biology, vol. 34, no. 2, pp. 165–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. J. W. Seo, H. Zhang, D. L. Kukis, C. F. Meares, and K. W. Ferrara, “A novel method to label preformed liposomes with C64u for positron emission tomography (PET) imaging,” Bioconjugate Chemistry, vol. 19, no. 12, pp. 2577–2584, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. H.-E. Wang, H.-M. Yu, Y.-C. Lu et al., “Internal radiotherapy and dosimetric study for I111n/L177u-pegylated liposomes conjugates in tumor-bearing mice,” Nuclear Instruments and Methods in Physics Research A, vol. 569, no. 2, pp. 533–537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. W.-C. Lee, J.-J. Hwang, Y.-L. Tseng et al., “Therapeutic efficacy evaluation of I111n-VNB-liposome on human colorectal adenocarcinoma HT-29/luc mouse xenografts,” Nuclear Instruments and Methods in Physics Research A, vol. 569, no. 2, pp. 497–504, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. Y.-J. Chang, C.-H. Chang, T.-J. Chang et al., “Biodistribution, pharmacokinetics and microSPECT/CT imaging of R188e-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model,” Anticancer Research, vol. 27, no. 4B, pp. 2217–2225, 2007. View at Google Scholar · View at Scopus
  73. Y.-J. Chang, C.-H. Chang, C.-Y. Yu et al., “Therapeutic efficacy and microSPECT/CT imaging of R188e-DXR-liposome in a C26 murine colon carcinoma solid tumor model,” Nuclear Medicine and Biology, vol. 37, no. 1, pp. 95–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. D. Emfietzoglou, K. Kostarelos, and G. Sgouros, “An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy,” Journal of Nuclear Medicine, vol. 42, no. 3, pp. 499–504, 2001. View at Google Scholar · View at Scopus
  75. A. Bao, B. Goins, R. Klipper, G. Negrete, and W. T. Phillips, “R186e-liposome labeling using R186e-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats,” Journal of Nuclear Medicine, vol. 44, no. 12, pp. 1992–1999, 2003. View at Google Scholar · View at Scopus
  76. A. Bao, B. Goins, R. Klipper, G. Negrete, and W. T. Phillips, “Direct T99mc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 2, pp. 419–425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. W. T. Phillips, R. Klipper, and B. Goins, “Novel method of greatly enhanced delivery of liposomes to lymph nodes,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 1, pp. 309–313, 2000. View at Google Scholar · View at Scopus
  78. S. X. Wang, A. Bao, S. J. Herrera et al., “Intraoperative R186e-liposome radionuclidetherapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model,” Clinical Cancer Research, vol. 14, no. 12, pp. 3975–3983, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Zavaleta, B. Goins, A. Bao, L. Mcmanus, C. A. Mcmahan, and W. Phillips, “Imaging of R186e-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis,” Journal of Drug Targeting, vol. 16, no. 7-8, pp. 626–637, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. L.-C. Chen, C.-H. Chang, C.-Y. Yu et al., “Biodistribution, pharmacokinetics and imaging of R188e-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model,” Nuclear Medicine and Biology, vol. 34, no. 4, pp. 415–423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. T.-H. Chow, Y.-Y. Lin, J.-J. Hwang et al., “Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model,” Anticancer Research, vol. 29, no. 6, pp. 2111–2120, 2009. View at Google Scholar · View at Scopus
  82. M.-Y. Change, J. Seideman, and S. Sofou, “Enhanced loading efficiency and retention of A225c in rigid liposomes for potential targeted therapy of micrometastases,” Bioconjugate Chemistry, vol. 19, no. 6, pp. 1274–1282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Sofou, B. J. Kappel, J. S. Jaggi, M. R. McDevitt, D. A. Scheinberg, and G. Sgouros, “Enhanced retention of the α-particle-emitting daughters of actinium-225 by liposome carriers,” Bioconjugate Chemistry, vol. 18, no. 6, pp. 2061–2067, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Sofou, J. L. Thomas, H.-Y. Lin, M. R. McDevitt, D. A. Scheinberg, and G. Sgouros, “Engineered liposomes for potential α-particle therapy of metastatic cancer,” Journal of Nuclear Medicine, vol. 45, no. 2, pp. 253–260, 2004. View at Google Scholar · View at Scopus
  85. H. Nakamura, M. Ueno, H. S. Ban et al., “Development of boron nanocapsules for neutron capture therapy,” Applied Radiation and Isotopes, vol. 67, no. 7-8, pp. S84–S87, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Yanagie, K. Maruyama, T. Takizawa et al., “Application of boron-entrapped stealth liposomes to inhibition of growth of tumour cells in the in vivo boron neutron-capture therapy model,” Biomedicine and Pharmacotherapy, vol. 60, no. 1, pp. 43–50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. K. J. Harrington, G. Rowlinson-Busza, K. N. Syrigos et al., “Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model,” Clinical Cancer Research, vol. 6, no. 12, pp. 4939–4949, 2000. View at Google Scholar · View at Scopus
  88. P. E. Huber, M. Bischof, J. Jenne et al., “Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy,” Cancer Research, vol. 65, no. 9, pp. 3643–3655, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Lammers, V. Subr, P. Peschke et al., “Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy,” British Journal of Cancer, vol. 99, no. 6, pp. 900–910, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. C.-H. Chang, M. G. Stabin, Y.-J. Chang et al., “Comparative dosimetric evaluation of nanotargeted R188e-(DXR)- liposome for internal radiotherapy,” Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 6, pp. 749–758, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. L.-C. Chen, C.-H. Chang, C.-Y. Yu et al., “Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of R188e-DXR-liposome in C26 colon carcinoma ascites mice model,” Nuclear Medicine and Biology, vol. 35, no. 8, pp. 883–893, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. T.-H. Chow, Y.-Y. Lin, J.-J. Hwang et al., “Diagnostic and therapeutic evaluation of I111n-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model,” Nuclear Medicine and Biology, vol. 35, no. 5, pp. 623–634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. Y.-Y. Lin, J.-J. Li, C.-H. Chang et al., “Evaluation of pharmacokinetics of I111n-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model,” Cancer Biotherapy and Radiopharmaceuticals, vol. 24, no. 4, pp. 453–460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. K. Kostarelos and D. Emfietzoglou, “Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals,” Anticancer Research, vol. 20, no. 5A, pp. 3339–3345, 2000. View at Google Scholar · View at Scopus
  95. A. M. Syme, S. A. McQuarrie, J. W. Middleton, and B. G. Fallone, “Dosimetric model for intraperitoneal targeted liposomal radioimmunotherapy of ovarian cancer micrometastases,” Physics in Medicine and Biology, vol. 48, no. 10, pp. 1305–1320, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Huwyler, J. Drewe, and S. Krähenbühl, “Tumor targeting using liposomal antineoplastic drugs,” International Journal of Nanomedicine, vol. 3, no. 1, pp. 21–29, 2008. View at Google Scholar · View at Scopus
  97. J. W. Park, C. C. Benz, and F. J. Martin, “Future directions of liposome- and immunoliposome-based cancer therapeutics,” Seminars in Oncology, vol. 31, no. 13, pp. 196–205, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Cheon and J.-H. Lee, “Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology,” Accounts of Chemical Research, vol. 41, no. 12, pp. 1630–1640, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. T. A. Elbayoumi and V. P. Torchilin, “Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines,” European Journal of Pharmaceutical Sciences, vol. 32, no. 3, pp. 159–168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. N. Kamaly, T. Kalber, M. Thanou, J. D. Bell, and A. D. Miller, “Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging,” Bioconjugate Chemistry, vol. 20, no. 4, pp. 648–655, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. A. N. Lukyanov, T. A. Elbayoumi, A. R. Chakilam, and V. P. Torchilin, “Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody,” Journal of Controlled Release, vol. 100, no. 1, pp. 135–144, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. P. Diagaradjane, J. M. Orenstein-Cardona, N. E. Colón-Casasnovas et al., “Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe,” Clinical Cancer Research, vol. 14, no. 3, pp. 731–741, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. R. Koole, M. M. van Schooneveld, J. Hilhorst et al., “Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging,” Bioconjugate Chemistry, vol. 19, no. 12, pp. 2471–2479, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. M. M. van Schooneveld, E. Vucic, R. Koole et al., “Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation,” Nano Letters, vol. 8, no. 8, pp. 2517–2525, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. E. Tasciotti, X. Liu, R. Bhavane et al., “Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications,” Nature Nanotechnology, vol. 3, no. 3, pp. 151–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Ganta and M. Amiji, “Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells,” Molecular Pharmaceutics, vol. 6, no. 3, pp. 928–939, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. M. C. Garnett and P. Kallinteri, “Nanomedicines and nanotoxicology: some physiological principles,” Occupational Medicine, vol. 56, no. 5, pp. 307–311, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Nel, T. Xia, L. Mädler, and N. Li, “Toxic potential of materials at the nanolevel,” Science, vol. 311, no. 5761, pp. 622–627, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. M. A. Dobrovolskaia, D. R. Germolec, and J. L. Weaver, “Evaluation of nanoparticle immunotoxicity,” Nature Nanotechnology, vol. 4, no. 7, pp. 411–414, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. K. R. Vega-Villa, J. K. Takemoto, J. A. Yáñez, C. M. Remsberg, M. L. Forrest, and N. M. Davies, “Clinical toxicities of nanocarrier systems,” Advanced Drug Delivery Reviews, vol. 60, no. 8, pp. 929–938, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. D. R. Fisher, S. Shen, and R. F. Meredith, “MIRD dose estimate report No. 20: radiation absorbed-dose estimates for I111n- and Y90-ibritumomab tiuxetan,” Journal of Nuclear Medicine, vol. 50, no. 4, pp. 644–652, 2009. View at Publisher · View at Google Scholar · View at Scopus